Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: the VELOCITY study
Event:
Heart Failure 2025
Topic:
Pharmacotherapy
Session:
Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease